Drugs / PEGLyte
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06831539 | Dec 2024 → Sep 2026 expected | cancer | University of Montreal Hospital Centre (CHUM) | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02976805 | Feb 2017 → Feb 2020 | — | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01398020 | Jul 2011 → Sep 2012 | — | University of British Columbia | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT01627171 Comparator | Sep 2012 → Dec 2013 | — | St. Joseph's Healthcare Hamilton | Unknown | No outcome recorded |
| Phase 4 | NCT00380497 Comparator | Sep 2006 → Sep 2007 | colonic duplication | The Hospital for Sick Children | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEGLyte | “Subjects will be asked to take 4L of Peglyte the day prior to procedure.” NCT01398020 ↗ |
| Known as | Polyethelene Glycol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01627171 ↗ |
| Route | Oral | “Subjects will be asked to take 4L of Peglyte the day prior to procedure.” NCT01398020 ↗ |